Rationale Ziprasidone is an atypical antipsychotic recommended to be administered twice daily. Objectives The purpose of this study was to investigate whether occupancy of the dopamine D 2/3 receptors by ziprasidone is maintained across a day employing a within subject design. Methods Positron emission tomography (PET) scans with [
Introduction
Ziprasidone is an atypical antipsychotic shown to be effective in the treatment of schizophrenia and schizoaffective disorder (Daniel et al. 1999; Hirsch et al. 2002; Simpson et al. 2005; Stahl et al. 2010) . Ziprasidone given 80-160 mg per day in divided dosage has been shown to be effective in treating positive, negative and affective symptoms with relatively low incidence of extrapyramidal side effects (EPS), weight gain and metabolic side effects (Citrome 2009 ). Since ziprasidone has a relatively short peripheral half-life (6-7 h), it is currently recommended to be taken in divided dosage-typically twice a day, with food (Caley and Cooper 2002) .
Positron emission tomography (PET) studies have demonstrated a therapeutic window of striatal dopamine D 2/3 receptor blockade by antipsychotics in vivo. Clinical response has been associated with 60-70 % D 2/3 receptor blockade and 80 % or more has been associated with EPS (Farde et al. 1988; Kapur et al. 1995 Kapur et al. , 2000a Pilowsky et al. 1993) . We have previously shown, using the radiotracer [ 11 C]-raclopride, that ziprasidone (40-160 mg/day) continued to occupy 56± 18 % of D 2/3 receptors at expected plasma trough levels (12-16 h post-dose) (Mamo et al. 2004) . Recently, Vernaleken et al. (2008) have shown using the radiotracer [
18 F]-fallypride, that ziprasidone (80-160 mg/day) continued to occupy 59 % of D 2/3 receptors in the putamen 7.4 h post-dose. These results taken together, ziprasidone may continue to significantly occupy D 2/3 receptors in the striatum at plasma trough levels.
However, the previous studies have employed a betweensubjects design, and have not demonstrated continued D 2/3 receptor occupancy beyond the predicted pharmacokinetics of ziprasidone within the same subjects with schizophrenia over time. A within-subjects design would more robustly determine whether there is a discrepancy between the time course of ziprasidone's plasma concentration and D 2/3 receptor occupancy in the striatum.
Using multiple [
11 C]-raclopride PET scans within the same subjects, we sought to characterize ziprasidone's (60 mg, twice a day) occupancy at the D 2/3 receptors in relation to its peripheral pharmacokinetics over the 24 h in patients with schizophrenia. Elucidating the relationship between ziprasidone's central occupancy and peripheral pharmacokinetics will help inform optimal dosage frequency in the future, an important predictor of treatment adherence and relapse.
Methods

Participants
Adult patients aged 18-60 years old with a Structured Clinical Interview for DSM-IV (SCID-IV) diagnosis of schizophrenia or related psychoses were recruited from March 2007 to March 2010. All patients were found capable to participate in the study using the McArthur Competence Assessment Tool for Clinical Research. Exclusion criteria were: a history of intolerance or contraindication to ziprasidone, treatment with long-acting antipsychotics (within the past 6 months before entry), substance abuse or dependence (within the past 6 months), pregnancy, clinically significant abnormality in electrocardiography including a QTc interval of 450 ms or greater at the time of screening, co-treatment with medications known to affect QTc interval, annual radiation dose that would exceed 20 mSv, a history of significant head trauma, unstable or uncontrolled medical conditions. The study was approved by the Research Ethics Board of the Centre for Addiction and Mental Health, Toronto, Canada, and all participants provided written informed consent. This trial has been registered in ClinicalTrials.gov (Identifier NCT00818298).
Treatment with ziprasidone
PET scanning was completed in eligible patients who were maintained on oral ziprasidone monotherapy at 120 mg/day in two equally divided doses for at least 1 week. Enrolled patients previously maintained on antipsychotics other than ziprasidone were switched to ziprasidone at a starting dosage of 20 mg twice a day, then titrated to 60 mg twice a day. Patients previously maintained on olanzapine >5 mg per day completed a 1-week cross-titration to minimize the risk for withdrawal effects. Patients previously maintained on ziprasidone were kept on a dosage of 60 mg twice a day for at least 1 week prior to scanning. Study medication was dispensed in blister packs and adherence was monitored through pill count at each visit. All psychotropic agents other than ziprasidone were kept constant throughout the study and patients taking any psychotropics known to affect dopamine blockade other than ziprasidone were excluded from the study.
Assessments
The following scales were used to assess participants at baseline and at the time of each PET scan-Clinical Global Impression (CGI) (Guy 1976 ) and the Positive and Negative Syndrome Scale (PANSS).
PET image acquisition [ 11 C]-raclopride PET scans were completed at one of three time points following 60 mg of oral ziprasidone: (mean + SD) 287 ± 12, 768 ± 81 and 1402 ± 46 min. Patients were taking ziprasidone twice daily, 60 mg each in the morning and at night, and one night dose was skipped before the 23-h scan. Usually patients had a 13-h scan in the morning after taking ziprasidone the night before, then again took the medication immediately after finishing the morning scan and scanned 5 h later, although this schedule was slightly modified according to the availability of the PET camera. We refer to these as the 5-, 13-and 23-h scans, respectively. We used a high-resolution neuro-PET camera system CPS-HRRT (Siemens Medical Imaging, Knoxville, TN, USA), which measures radioactivity in 207 brain sections with a thickness of 1.2 mm each. The in-plane resolution of the scanner was 2.8 mm full-width at halfmaximum. Transmission scans were acquired for 5 min using a single photon point source, 137 Cs (T=30.2 year, Eγ= 662 keV) and used to correct the emission scans for the attenuation of 5 11 keV photons through tissue and head support. The emission data were acquired in list mode, thereby affording the highest possible temporal resolution. A customfitted thermoplastic mask (Tru-Scan Imaging, USA) was made for each subject and used with a head fixation system during PET scans in order to reduce any movement during the acquisition. No statistical differences were observed in injected dose, specific activity and mass of [ 11 C]-raclopride among the PET scan sessions. A mean radioactivity dose of 9.91 ± 0.71 mCi with a specific activity of 2000 ± 621 mCi/mmol and mass of 1.92±0.72 μg was injected as a bolus, followed by a flush with 2 ml saline into an intravenous line placed in an antecubital vein. Scanning time was 60 min and 28 frames (5 one-minute, 20 two-minute and 3 five-minute frames) were then defined.
MRI image acquisition
Patients were scanned with a 1.5T Signa scanner (General Electric Medical Systems, Milwaukee, WI) to acquire a proton density image (TE = 17, TR = 6000, FOV=22 cm 2D, 256×256, slice thickness of 2 mm, NEX=2). The MRI images were used for the analysis of the PET scans.
Image analysis
The analysis of the PET images was performed as previously described (Graff-Guerrero et al. 2008 ). The quantitative estimate of binding was estimated using the simplified reference tissue method (Lammertsma et al. 1996) with the cerebellar cortex as the reference region and caudate, putamen and ventral striatum as regions of interest (ROIs). This method has been validated to reliably estimate binding potential nondisplaceable (BP ND ), which is the typical measurement from reference tissue methods, as it compares the concentration of radioligand in receptor-rich to receptor-free regions (Innis et al. 2007 ). BP ND was estimated using the software PMOD v2.7 (PMOD Technologies Ltd., Zurich, Switzerland).
Receptor occupancy was defined as the percentage of reduction in the BP ND from a baseline state to the treated state. In order to calculate receptor occupancy, a measure of baseline BP ND in the antipsychotic-free (untreated) state was necessary. Since we were unable to obtain the baseline measures of receptor occupancy from the patients (when they were antipsychotic free) within our current design, we extrapolated the baseline BP ND for each subject using our pooled data previously obtained from 44 age-and sexmatched healthy controls.
The occupancies were estimated with the following formula:
Nonlinear regression analysis was applied to correlate the plasma level of ziprasidone with receptor occupancy. The data were fit to a rectangular hyperbola (one-site binding model) described by the equation:
, where ED 50 represents the serum level of ziprasidone resulting in 50 % receptor occupancy and X corresponds to the ceiling receptor occupancy. In the model, X was fixed to 100 and ED 50 >0. The ED 50 was estimated for the ROIs combined. The time-course of receptor occupancy across the ROIs, indicating a central receptor occupancy half-life, was estimated by a one-phase exponential decay equation: where half-life is 0.6932/K and X corresponds to the ceiling receptor occupancy.
Serum ziprasidone and prolactin quantification
Serum ziprasidone levels were obtained immediately before tracer injection and before the end of the PET scan, 60 min apart, and the average value whenever available was used to estimate the ED 50 . They were determined using liquid chromatography with mass spectroscopy detection. Deuterated ziprasidone was used as the internal standard. Calibration curves were linear from 7.5 to 600 nmol/L, with 7.5 nmol/L being the limit of quantification and 3.0 nmol/L the limit of detection. The intra-assay coefficient of variation was less than 5 %. Serum prolactin was measured immediately before tracer injection using the Beckman Coulter Access 2 instrument (reference range: male 3-13 μg/L; female 3-27 μg/L). The methodology utilizes paramagnetic particles in a chemiluminescent immunoassay. The reporting limit was 1 μg/L.
Statistical analysis
Wilcoxon signed rank test, Mann-Whitney's U test, t test and Spearman's rank correlation coefficient were utilized as applicable. Statistical analyses were performed with SPSS (version 17.0, SPSS Inc, Chicago, IL) and a p-value of <0.05 was considered significant (two tailed).
Results
Sample characteristics
Fourteen ambulatory patients meeting eligibility criteria were enrolled in the study. Antipsychotics prior to enrolling in the study were olanzapine (n = 6), ziprasidone (n=4), quetiapine (n=2) and risperidone (n=2). Two subjects (one on olanzapine and one on risperidone) showed clinical deterioration during the switching/cross-titration and were withdrawn from the study before completing the PET scans. Twelve subjects (six female) with a diagnosis of schizophrenia underwent the PET scanning procedures. One subject did not complete the 13-h scan due to clinical deterioration. In another subject, the 5-h scan data were not analyzable due to an interruption of the scan and the 23-h scan data were not analyzable due to technical problems. Excluding these three scans, there were 11 scans per time point. Participants were on average 37.4 (±12.8) years of age and had a mean illness duration of 14.5 (±12.7) years. The study was not powered to address the clinical efficacy of ziprasidone and the results are presented for descriptive purposes only. The average total PANSS score for the 12 patients was 53.5 (±13.7) at baseline while the CGI-severity was 2.9 (±1.2), reflecting an overall mild severity. From baseline to the time of the respective PET scans, no significant differences were noted in any of the PANSS subscales. Similarly, CGI-change scores did not reveal a pattern of clinical deterioration during the scanning interval. At the time of the 5-/13-/23-h scans, CGI-change scores compared to baseline were 3 (minimally better) for 2/3/1 patients, 4 (no change) for 7/6/8 and 5 (minimally worse) for 2/2/2, respectively. Serum ziprasidone and prolactin levels Figure 1 shows ziprasidone levels both before and after each PET scan. For one patient, post-scan level was not available and pre-scan level (at 23 h post-dose) was utilized for analysis. Pre-scan ziprasidone levels were higher both at 5 versus 13 h (Z=−2.578, p=0.010), and higher at 13 versus 23 h (Z=−2.934, p=0.003). Pre-scan levels were significantly higher than post-scans at 13 h in all cases. At 5 h, pre-scan levels were higher than post-scan levels in 10 of 12 subjects but the difference did not reach statistical significance. At 23 h, pre-and post-scan levels did not differ significantly.
Prolactin levels were higher than the reference range in seven patients at 5-h (mean±SD: 23.5±13.6 μg/L, n=12), two at 13-h (9.6±9.4 μg/L, n=11) and zero at 23-h (5.1± 3.7 μg/L, n=12). Prolactin levels were higher at 5 h than 13 h (Z=−2.934, p=0.003), and higher at 13 h than 23 h (Z=−1.994, p=0.046).
PET data Radiochemical characteristics of [
11 C]-raclopride at 5-, 13-and 23-h postziprasidone scans were as follows: injected dose 10.1±0.69, 9.75±0.82 and 9.90±0.65 mCi; specific activity 2230±573, 1792±699 and 1979±557 mCi/mmol; injected mass 1.68±0.49, 2.18±0.90 and 1.90±0.69 μg, with no significant differences in the values across the scans. As is shown in Table 1 and Fig. 2 , ziprasidone produced a clinically relevant D 2/3 receptor occupancy 5 h after administration in the ROIs, which decreased at 13 h and was equivalent to the baseline level of controls at 23 h. There were no significant differences between the left and the right ROIs. Figure 3 shows serum ziprasidone levels versus D 2/3 occupancy across the ROIs. There was a significant positive correlation in the putamen (n=33, rho=0.802, p=0.000), caudate (n=33, rho=0.846, p=0.000) and ventral striatum (n=33, rho=0.789, p=0.000). The ED 50 across the ROIs was 
Discussion
To our knowledge, there have been five published PET studies evaluating central dopamine occupancy by ziprasidone (Bench et al. , 1993 Lammertsma et al. 1996; Mamo et al. 2004; Vernaleken et al. 2008) . However, this is the first study to assess ziprasidone's central binding at three time points using a within-subject design. Our results indicate that ziprasidone, as dosed in this study, has a mean occupancy of 66 % in the putamen 5 h after administration, which then declines to 39 % at 13 h and 2 % at 23 h, corresponding to an estimated central half-life of ziprasidone of 8.3 h. Thus, the time-course of the drug's central binding mirrors its known peripheral pharmacokinetics (peripheral half-life of 6-7 h). The serum ziprasidone levels we observed 13 h post-dose in this study (150±103 nmol/L; median: 114 nmol/L) are consistent with data reported at trough in a larger therapeutic drug monitoring sample (median: 125 nmol/L for 120 mg/day) (Cherma et al. 2008) . In contrast, the occupancy at 13 h (39±26 %) was slightly lower than that reported in previous PET studies (Mamo et al. 2004; Vernaleken et al. 2008) , as well as a single photon emission tomography study that found D 2/3 receptor occupancy of 60 % at 12 h post-dose (Corripio et al. 2005) . We observed no appreciable drug binding 23 h after the last dose of 60 mg, consistent with an earlier report in healthy subjects using a single dose of 40 mg .
Our results contrast with those reported by , possibly attributable to differences in study design and methodology. Specifically, Vernaleken et al. (2008) did not employ a within-subject design, but instead compared occupancy in seven subjects 7.4 h after ziprasidone administration and in eight other subjects 21.4 h after ziprasidone administration. By employing a within-subject design, our study presumably better controls for the large interindividual variability in the pharmacokinetics and dopamine D 2/3 receptor occupancy of ziprasidone over time. Notably, Vernaleken et al. also used higher doses in their study (range, 120-200 mg/day; mean±SD 153±34 mg/day), versus a fixed dose of 60 mg BID in our study.
We found the serum level of ziprasidone resulting in 50 % receptor occupancy was estimated to be 84 ng/ml, which was higher than the previously reported values of 39-64 ng/ml (depending on the brain region) by and 33 ng/ml by Mamo et al. (2004) . It has been pointed out that a range of 50-200 ng/ml for ziprasidone may be effective ) but it has also been identified that heterogeneity in levels is substantial with this medication, both centrally ) and peripherally (Cherma et al. 2008) . While this point is highly relevant in trying to translate the results of PET data to peripheral therapeutic drug monitoring (TDM) that is more easily applicable, and efforts are ongoing to better model pharmacokinetics of the medication (Wessels et al. 2011) and to predict central occupancy levels using peripheral drug levels (Uchida et al. 2011) , it has been reported that blood levels of ziprasidone failed to filter out responders, with no correlations observed between improvements or side effects and doses or serum levels (Vogel et al. 2009 ).
As such, TDM of ziprasidone may currently be of limited use in real-world clinical practice although more studies are necessary. Our results bear closer resemblance to those with quetiapine and clozapine, for which no occupancy has been shown 1 day after the last dose (Kapur et al. 1999 (Kapur et al. , 2000b Suhara et al. 2002) ; they also stand in a sharp contrast to the longer central than peripheral pharmacokinetics reported with olanzapine and risperidone (Tauscher et al. 2002) as well as aripiprazole ). However, ziprasidone, which has a dissociation constant (K) between 2.7 and 6 nM, exhibits in vitro more than 20-fold higher affinity for the dopamine D 2 receptors in comparison to clozapine (K=76 to 180 nM) and quetiapine (K= 140 to 680 nM) (Seeman 2011) . The rapid central decrease in D 2/3 receptor occupancy we observed with ziprasidone may entirely be associated with a short central half-life that mirrors the peripheral half-life. This is in contrast to the combination of loose binding, fast dissociation and short central half-life described with quetiapine (Kapur et al. 2000b ) and clozapine (Suhara et al. 2002) . In addition, the short central occupancy half-life may contribute to its relatively low incidence of EPS at clinical doses (Citrome 2009 ). The time-course of striatal occupancy also was mirrored by a similar rate of decline in plasma prolactin levels, lending further support to our main finding. Further, a marked discrepancy in occupancy values between singleand multiple-dose administration has been observed with ziprasidone . Potential upregulation in D 2 receptors upon chronic administration of ziprasidone (Heard et al. 2008 ) might account for somewhat higher binding potentials after 23 h in patients versus controls and worsening that was noted in some patients as well. Taken together, more work is necessary to better characterize this unique antipsychotic medication that binds tightly to dopamine receptors.
A major strength of this study is its within-subject design using [
11 C]-raclopride, a radiotracer with well-established test-retest stability (Uchida et al. 2009 ), and any residual effects from the previous antipsychotics are unlikely to affect dopamine blockade with ziprasidone under a steady state in a significant manner. Limitations of this study include a relatively small number of participants, precluding analysis of differences between responders and nonresponders. Similarly, observed gender differences warrant replication in view of the small sample. The absence of baseline (untreated) PET data in subjects with schizophrenia is another potential limitation shared with most PET studies examining antipsychotic medications in patients with schizophrenia. However, having a "baseline" scan in the absence of any antipsychotics would be difficult and can be ethically problematic. Further, exposing subjects to many PET scans is not without risks and our facility regulates that a volunteer can have only up to 4 PET scans per year to protect safety. In addition, the magnitude of the error due to using a baseline obtained from healthy controls is estimated to be low: 0-4 % for patients with an 80 % occupancy and 0-9 % for those with a 50 % occupancy (Farde et al. 1992; Kapur et al. 1996) , although a small elevation in receptor availability is still possible (Howes et al. 2012) and caution is warranted in extrapolating data from healthy controls. Our interest was confined to striatal dopamine D 2/3 receptors 11 C]-raclopride. While ziprasidone may show some preferential extrastriatal binding , the affinity of [ 11 C]-raclopride for dopamine D 2/3 receptors precludes accurate measurements of binding in extrastriatal regions. Furthermore, ziprasidone acts on multiple receptors and transporters (Stahl and Shayegan 2003) including serotonergic 5-HT 2A receptors for which central kinetics is reported to be longer (Fischman et al. 1996) , as well as 5-HT 1A receptors (Frankle et al. 2011) . Finally, our study adopted a fixed-dose design that might not reflect its dosing in clinical situations ).
We found that 13 h after the last dose of ziprasidone, the dopamine D 2/3 occupancy was well below the suggested 60 % therapeutic threshold for PET studies with [
11 C]-raclopride. This time is expected to reflect the trough occupancy when ziprasidone is taken twice a day. Some antipsychotics such as clozapine and quetiapine have been shown to be clinically effective notwithstanding the fact that they are associated with transient and/or loose binding at D 2/3 receptors (Kapur et al. 2000b; Mamo et al. 2008; Nordstrom et al. 1995; Pickar et al. 1996) . This raises the possibility that ensuring 24-h continuous D 2/3 blockade above 60 %, as predicted by the drugs' pharmacokinetics, may not be a prerequisite to maintain wellness in schizophrenia. Nevertheless, our results suggest that in order to maintain continuous dopamine D 2/3 receptor blockade, ziprasidone should be administered in its currently recommended divided dosage. In published studies, and in this study, some patients remain stable when they receive ziprasidone twice a day. However, more work is necessary to understand how the central occupancy of antipsychotics like ziprasidone relates to their clinical efficacy and tolerability. Well-designed clinical studies are necessary to quantify the risks and benefits of once daily versus twice-daily dosing of ziprasidone.
This study was the first to examine within-subject changes in ziprasidone's occupancy at the dopamine D 2/3 receptors over 24-h using [
11 C]-raclopride. Our findings lead us to conclude there is no discrepancy between the time course of ziprasidone's plasma concentration and dopamine D 2/3 receptor occupancy in the brain.
